HROW · Harrow, Inc.
$42.06
+0.42 (+1.01%)
At close · Aug 20
Market Cap
$1.56B
Shares
37.49M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$42.06
Open$41.64
Day$41.24–42.71
52W close$29.03–54.80
Avg vol 30d571K
Short int6.8M · 18.1% float · 11.8d
Short vol75%
Last earningsAug 11, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 10
Up next
Next earnings call
Nov 12, 2026
Est · unconfirmed
· in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 10, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+2%
above
Price vs 50-day avg
+2%
above
RSI (14)
58
neutral
MACD trend
Positive
52-week position
51%
mid-range
Momentum
relative strength
1-month return
0%
trailing
6-month return
−22%
trailing
YTD return
−14%
this year
Relative strength
−34%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $41 › 200d $41 — 200d above 50d
Institutional flow
Accumulating
+1% holders QoQ · +41 funds added
Insider flow
Distributing
Net -$450.0K over 90 days · 100% sells
Short interest
Falling
18.09% of float · ▼ -0.9% MoM · 11.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
222 holders — near 3-yr high, broad support
Squeeze score
85
high risk · 0–100
Fundamentals
Revenue growth
+36%
Y/Y
Gross margin
75%
contracting
EPS growth
+71%
Y/Y
Free cash flow
$43.0M
Balance sheet
$177.1M
net debt
Quant / Vol
risk profile
Volatility
65%
annualized · 1-yr
Max drawdown
−47%
past year
ATR
5.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 10, 2026
full-year 2026
Revenue
Initiated
$350M – $365M
prior FY $272.3M
midpoint +31.3% Y/Y
Adjusted EBITDA
Non-GAAP
Initiated
$80M – $100M
2027
TYRVAYA revenue
at least $30M
Prior guidance
period ended
· from the 8-K filed May 11, 2026
Revenue
· Second Quarter
$71M – $81M
Guided vs delivered
· last 4 settled
Full-year revenue
full-year 2025
guided $270M – $280M
$272.3M
In line
Revenue
2023
guided $129M – $136M
$130.19M
In line
Revenues
2024
guided at least $180M
$199.61M
In line
The new range
Q4 2023
guided $35M – $44M
$36.36M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+2%
Bullish
Price vs 50-day avg
+2%
Bullish
RSI (14)
58
Neutral
MACD trend
Positive
Bullish
52-week position
51%
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $41 › 200d $41 — 200d above 50d
Institutional flow
Accumulating
+1% holders QoQ · +41 funds added
Insider flow
Distributing
Net -$450.0K over 90 days · 100% sells
Short interest
Falling
18.09% of float · ▼ -0.9% MoM · 11.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
222 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $29
Now $42 · 51%
Range high $55
vs 200-day avg +2%
vs 50-day avg +2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -$13,891,000 | Six Months Ended June 30, 2026 | — |
|
|
|||
| IHEEZO First-ever ordering accounts in the quarter | 62 | Q2 2026 | — |
| IHEEZO Reorder rate | 85.5% | Q2 2026 | — |
| IHEEZO Total ordering accounts | 224 | Q2 2026 | — |
| IHEEZO trailing twelve-month reorder rate | 85.5% | Q2 2026 | — |
| IHEEZO Unit demand | 65,477 | Q2 2026 | — |
| TRIESENCE Total ordering accounts | 805 | Q2 2026 | — |
| TRIESENCE Unit demand | 14,529 | Q2 2026 | — |
| VEVYE Branded TRx market share | 14.6% | Q2 2026 | — |
| VEVYE New prescriptions (NRx) sequential growth | 4% | Q2 2026 | — |
| VEVYE Total prescriptions (TRx) sequential growth | 21% | Q2 2026 | — |
| VEVYE Unique prescribers sequential growth | 15% | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HROW
this stock
Harrow, Inc.
|
$1.56B | -14.2% | +36.4% | — | 18.1% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$64.91B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$57.85B | +16.3% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$50.24B | +1.7% | — | — | 0.0% |
|
HLN
Haleon plc
|
$43.41B | -2.4% | — | — | 0.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HROW | +8.2% | +0.4% | -22.4% | +8.5% | -14.2% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +10.2% | -2.9% | -33.5% | +6.4% | -26.0% |
Key facts
CIK
1360214
CUSIP
415858109
13F (30d)
203 filings
199 filers
Visit website
Investor relations